UNCY (Unicycive Therapeutics) FY2025 Earnings & Business Update

Price: ~$6.30 Market Cap: ~137.33M Stage: Clinical (NDA under review) Focus: Kidney disease. Lead asset oxylanthanum carbonate (OLC), oral phosphate binder for hyperphosphatemia in CKD dialysis patients

The Numbers

• Revenue: Zero. Pre-revenue, NDA stage

• R&D FY2025: $9.1M (down from $20.0M, drug development and clinical trial costs wound down as NDA shifted to regulatory phase)

• G&A FY2025: $20.4M (up from $12.1M, commercial launch prep, consulting, professional services ramping)

• Net Loss FY2025: $26.6M ($1.67/share, improved from $37.8M/$5.65 per share in 2024)

• Other Income: $3.0M (vs $4.6M expense in 2024, driven by warrant liability remeasurement)

• Cash (March 30, 2026 unaudited): $54.9M including marketable securities

• Runway: Into 2027

$54.9M in cash with the NDA under review is a reasonable position. They're not running a Phase 3 anymore, just commercial prep and G&A burn. The $20.4M G&A tells you they're building the commercial infrastructure now.

Pipeline

• OLC (oxylanthanum carbonate): NDA resubmitted December 2025 after addressing CMC (manufacturing) issues from original submission. FDA accepted the resubmission January 2026. PDUFA date June 29, 2026. FDA raised no concerns on preclinical, clinical, or safety data in the original NDA. The resubmission was purely manufacturing-related. Supported by Phase 1, bioequivalence, and tolerability studies

• UNI-494 (acute kidney injury): Orphan drug designation for prevention of delayed graft function in kidney transplant. Phase 1 completed. Earlier stage, not the near-term story

The Market

Hyperphosphatemia affects roughly 75% of US dialysis patients. Current phosphate binders (sevelamer, calcium-based binders, Velphoro) work but have significant pill burden. Some patients take 9-12 pills per day. OLC's pitch is a differentiated clinical profile with reduced pill burden. If they can meaningfully cut the daily pill count while matching efficacy, that's a real commercial differentiator in a large, established market.

Catalysts

• PDUFA June 29, 2026. Binary event. This is the whole story right now

• Commercial launch targeted Q3 2026 if approved

The Risk

This is an NDA resubmission, not a first filing. The original NDA had manufacturing issues significant enough that the FDA didn't approve it. The resubmission specifically addresses the CMC concerns with the third-party drug product manufacturer. If the FDA is satisfied with the manufacturing fix, approval should be straightforward since they had no issues with the clinical or safety data. But CMC problems can be sticky. If the manufacturing still isn't right, it's another cycle.

Bottom Line

Single-asset NDA story with a June 29 PDUFA. Clean clinical data, manufacturing was the only issue. Cash is fine for launch. The hyperphosphatemia market is established and competitive but OLC's reduced pill burden could carve out share. Everything hinges on June 29.